Global fibrinolytic capacity in colorectal cancer: A new clue to occult fibrinolysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 2, 2003, Pages 151-154

  Ozturk, Mustafa ^a   Sengul, Neriman ^a   Dagli, Mehmet ^a   Kosar, Ali ^a   Bavbek, Nüket ^a,b  

^a FATIH UNIVERSITY   (Turkey)

^b Harbiye Mah   (Turkey)

Author keywords

Colorectal cancer; Disseminated intravascular coagulation; Global fibrinolytic capacity; Primary fibrinolysis

Indexed keywords

APROTININ; D DIMER; FIBRIN; HEMOGLOBIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ASSAY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0038724307     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900210     Document Type: Article

References (19)

1. Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338:1169.
2. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996;10:457.
3. Donati MB. Cancer and thrombosis: From phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278.
4. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846.
5. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy risk analysis using medicare claims data. Medicine 1999;78:285.
6. Edwards RL, Rickles FR, Moritz TE. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596.
7. Hagedorn AB, Bowie EJ, Elveback LR, et al. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1974;49:647.
8. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147.
9. Nand S, Fisher SG, Salgia R, et al. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic. J Clin Oncol 1987; 5:1998.
10. Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Eur J Cancer 1977;13:1053.
11. Sun NC, McAfee WM, Hum GJ, et al. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10.
12. Wajima T. Fibrinolytic profiles in patients with small cell carcinoma of the lung. Semin Thromb Hemost 1991; 17:280.
13. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992;11:237.
14. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000,96:3302.
15. Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 1973;139: 499.
16. Peuscher FW, Cleton FJ, Armstrong L. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980;96:5.
17. Goldberg MA, Ginsburg D, Mayer RJ. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987;69:187.
18. Choate JJ, Mosher DF. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer 1983;51:1142.
19. Walenga JM, Fareed J, Mariani G. Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B-beta 15-42 sequence. Semin Thromb Hemost 1984;10:252.